Bessemer Group’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Bessemer Group's NKTR Position: Q3 2026 in Review
Bessemer Group held its Nektar Therapeutics (NKTR) position steady in Q3 2026 at 1,565 shares worth $95K. The position accounts for ﹤0.01% of the portfolio, ranked #1532.
Bessemer Group first reported a position in NKTR in Q4 2014 and has held it in 21 quarters since. The position peaked at $112K in Q1 2026. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- Bessemer Group held 1,565 shares of Nektar Therapeutics worth $95K as of Q3 2026.
- Bessemer Group left its Nektar Therapeutics share count unchanged in Q3 2026.
- Nektar Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q3 2026, its #1532 holding.
- Bessemer Group first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 21 quarters since.
- Bessemer Group's Nektar Therapeutics position peaked at $112K in Q1 2026.
- 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.